major depressive disorder

Sage Therapeutics Depression Drug Fails in Phase 3, Shares Fall 60%
Sage Therapeutics Depression Drug Fails in Phase 3, Shares Fall 60%
Xconomy
SAGE Therapeutics
clinical trials
SAGE-217
major depressive disorder
Flag link:
FDA tags psilocybin drug as clinical depression Breakthrough Therapy
FDA tags psilocybin drug as clinical depression Breakthrough Therapy
Pharmaforum
FDA
psilocybin
major depressive disorder
Usona
PSIL201
Flag link:
VistaGen fails phase 2 depression trial, sparking stock rout
VistaGen fails phase 2 depression trial, sparking stock rout
Fierce Biotech
VistaGen
AV-101
major depressive disorder
clinical trials
Flag link:
Upcoming events – Sage targets depression and Biogen aims for lupus
Upcoming events – Sage targets depression and Biogen aims for lupus
EP Vantage
SAGE Therapeutics
SAGE-217
major depressive disorder
Biogen
BIIB059
lupus
Flag link:
FDA Overlooked Red Flags In Drugmaker’s Testing of New Depression Medicine
FDA Overlooked Red Flags In Drugmaker’s Testing of New Depression Medicine
KHN
FDA
Janssen
Spravato
esketamine
major depressive disorder
Flag link:
Otsuka, Click to develop digital therapeutics for MDD
Otsuka, Click to develop digital therapeutics for MDD
Pharmaceutical Business Review
Otsuka
Click Therapeutics
digital therapeutics
major depressive disorder
Flag link:
More data could be key for Alkermes after FDA panel vote
More data could be key for Alkermes after FDA panel vote
BioCentury
Alkermes
ALKS 5461
major depressive disorder
FDA
Flag link:
Alkermes Depression Drug Faces Long Odds After FDA Advisors Say No
Alkermes Depression Drug Faces Long Odds After FDA Advisors Say No
Xconomy
Alkermes
FDA
advisory panels
ALKS-5461
major depressive disorder
Flag link:
FDA Blasts Data, Trial Design For Alkermes Depression Drug
FDA Blasts Data, Trial Design For Alkermes Depression Drug
Xconomy
FDA
Alkermes
ALKS 5461
clinical trials
major depressive disorder
Flag link:
Janssen, Lundbeck and Takeda Raise Issues With FDA Draft Guidance on MDD Drugs
Janssen, Lundbeck and Takeda Raise Issues With FDA Draft Guidance on MDD Drugs
RAPS.org
FDA
JNJ
Janssen
Lundbeck
Takeda
major depressive disorder
drug development
Flag link:
Sage to Expedite Development of SAGE-217 in Major Depressive Disorder and Postpartum Depression
Sage to Expedite Development of SAGE-217 in Major Depressive Disorder and Postpartum Depression
CP Wire
SAGE Therapeutics
FDA
breakthrough status
SAGE-217
major depressive disorder
postpartum depression
Flag link:
Sage to Expedite Development of SAGE-217 in Major Depressive Disorder and Postpartum Depression
SAGE Therapeutics
SAGE-217
major depressive disorder
postpartum depression
Flag link:
Acceptance Growing for BrainsWay’s Depression Therapy
Acceptance Growing for BrainsWay’s Depression Therapy
Medical Devices and Diagnostics Industry
Brainsway
devices
Deep Transcranial Magnetic Stimulation
major depressive disorder
Flag link:
Study Shows Genetic Test Guided Treatment Significantly Improves Outcomes in Patients with Major Depressive Disorder
Study Shows Genetic Test Guided Treatment Significantly Improves Outcomes in Patients with Major Depressive Disorder
CP Wire
Assurex Health
GeneSight
major depressive disorder
Myriad Genetics
diagnostics
Flag link:
Study Shows Genetic Test Guided Treatment Significantly Improves Outcomes in Patients with Major Depressive Disorder
Assurex Health
GeneSight
major depressive disorder
Flag link:
FDA Now Accepts Alkermes Application It Rejected Two Weeks Ago
FDA Now Accepts Alkermes Application It Rejected Two Weeks Ago
CP Wire
Alkermes
ALKS-5461
major depressive disorder
FDA
Flag link:
Alkermes' Bad News Could Be Good News for Johnson & Johnson
Alkermes' Bad News Could Be Good News for Johnson & Johnson
Motley Fool
Alkermes
JNJ
ALKS-5461
esketamine
major depressive disorder
Flag link:
Why FDA News About Alkermes ALKS 5461 Studies Is Not A Complete Surprise
Alkermes
ALKS 5461
major depressive disorder
Flag link:
FDA Rejects Alkermes NDA for Major Depressive Disorder Drug ALKS 5461
FDA Rejects Alkermes NDA for Major Depressive Disorder Drug ALKS 5461
CP Wire
Alkermes
FDA
depression
major depressive disorder
ALKS 5461
Flag link:
Sage Shares Soar Again As Depression Drug Hits Mark in Phase 2 Test
Sage Shares Soar Again As Depression Drug Hits Mark in Phase 2 Test
Xconomy
SAGE Therapeutics
major depressive disorder
SAGE-217
Flag link:

Pages